Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105092 · ClinicalTrials.gov registry record · Phase 2
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT00105092: Completed Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company.
NCT00105092 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants, below the 234-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00105092, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Conditions Studied
Interventions
- DRUG Enzastaurin HCL
Study Locations (3)
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Tampa
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Nashville
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00105092 record still lists
NCT00105092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 234-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Enzastaurin HCL is the first listed.
NCT00105092 reports a single indexed study location in Florida, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT00105092 about?
NCT00105092 is a clinical study titled "Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.". Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
What is the current status of trial NCT00105092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00105092 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00105092?
The interventions under investigation include: Enzastaurin HCL (DRUG).
Who is sponsoring clinical trial NCT00105092?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105092 being conducted?
This trial has 3 study locations across Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00105092's enrollment target sits among peer trials
50 23rd of 30 higher than 8 of 30 other Non-Small-Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small-Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
-
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia